Dual-centre double blind randomised controlled trial (RCT) on the utility of personalised bronchiectasis action management plans (BAMP) for children with bronchiectasis

Bronchiectasis Action Management Plan (BAMP) for children with bronchiectasis

Although regarded as an ‘orphan disease’, bronchiectasis (BE) remains a major contributor to chronic lung morbidity and mortality in Indigenous people. Indigenous children are often hospitalised which involves urgent transportation of children from remote communities. The prevalence of BE among Northern Territory Indigenous children is very high (one in every 63-68). Also, BE is not rare among non-Indigenous children, despite common belief.

In children with asthma, personalised asthma action plans are recommended in all settings as there is robust evidence that its use improves clinical outcomes [e.g. reduced acute doctor visits, hospitalisations and improved quality of life (QoL)]. It is likely, but currently unknown, if BE action management plans (BAMP) are also beneficial for people with BE. There are no studies in children or adults with BE, therefore it is not surprising that BAMP is not routinely used, even in tertiary centres.

Providing each patient with a personalised BAMP adds substantial time spent during routine clinical consultations which is an issue as doctors are increasingly asked to do more with less available clinical time. Thus, a trial to determine the effectiveness of BAMP is needed before this can be successfully implemented in routine clinical care.


  • Dr Gabrielle McCallum

  • Professor Anne Chang

  • Menzies School of Health Research

  • January - December 2018

Back To The Projects